Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872940 | 0.93 | MKNK1 (0.42) | CYP2C9HPGDPIM1HTR2CDRD2 | |
| SCHEMBL5795447 | 0.92 | PIM1 (0.41) | ALDH1A1HTTPIM1HTR2CDRD2 | |
| SCHEMBL5872872 | 0.92 | MKNK1 (0.45) | HTTPIM1HTR2CDRD2DRD3 | |
| SCHEMBL5872873 | 0.92 | CYP2C9 (0.47) | CYP2C9PIM1KDM5A | |
| SCHEMBL5773190 | 0.91 | HTR2C (0.45) | HPGDALDH1A1HTTPIM1HTR2C | |
| SCHEMBL5873211 | 0.91 | CYP2C9 (0.48) | CYP2C9PIM1KDM5A | |
| SCHEMBL5774021 | 0.89 | NPC1 (0.44) | CYP2C9HPGDALDH1A1TSHRHTT | |
| SCHEMBL5769674 | 0.89 | PIM1 (0.40) | CYP2C9ALDH1A1HTTPIM1KDM5A | |
| SCHEMBL5772558 | 0.89 | ADORA2A (0.39) | HTTPIM1ADORA2BADORA2AKDM5A | |
| SCHEMBL5873060 | 0.88 | DYRK1A (0.40) | CYP2C9PIM1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | CYP2C9 695/4885HPGD 378/4885ALDH1A1 2272/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | CYP2C9 695/4885HPGD 378/4885ALDH1A1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.